Cleave Biosciences Receives $42,000,000 Series A Financing Round

  • Feed Type
  • Date
    10/11/2011
  • Company Name
    Cleave Biosciences
  • Mailing Address
    Undisclosed Burlingame, CA 94010
  • Company Description
    The big idea at Cleave is to develop small-molecule chemical compounds that will interact with certain protein pathways that get thrown out of whack in patients with cancer.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $42,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    None of Cleave’s drug candidates are ready yet for clinical trials, but the financing will give the company three to four years of operating cash to pursue that goal.
  • M&A Terms
  • Venture Investor
    Clarus Ventures
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    5AM Ventures
  • Venture Investor
    Astellas Venture Management
  • Venture Investor
    OrbiMed

By posting a comment, you agree to our terms and conditions.